Scorpius Holdings Inc (SCPX) - Financial and Strategic SWOT Analysis Review
Description
Scorpius Holdings Inc (SCPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Scorpius Holdings Inc (Scorpius), formerly known as NightHawk Biologics Inc, operates through its subsidiary, Scorpius BioManufacturing, as a contract development and manufacturing organization (CDMO). It is focused on biologics manufacturing services. The company combines biomanufacturing expertise with advanced techniques in immunoassays and bioanalytical methods to produce cell- and gene-based therapies, as well as large molecule biologics. Its services cater to biotechnology and biopharmaceutical industries, supporting the production of cell- and gene-based therapies and large molecule biologics. Scorpius offers services, including drug substance manufacturing, release testing, and process development, supporting clients from early preclinical stages to commercial launch and addressing the growing demands in biopharmaceutical manufacturing. It operates through a storage and testing facility in San Antonio, Texas, which features modular cleanroom space and single-use bioreactors. Scorpius is headquartered in Morrisville, North Carolina, the US.
Scorpius Holdings Inc Key Recent Developments
May 05,2025: Scorpius Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
Apr 30,2025: Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
Nov 14,2024: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
Oct 31,2024: Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected To Save Over $2 Million Annually
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Scorpius Holdings Inc (Scorpius), formerly known as NightHawk Biologics Inc, operates through its subsidiary, Scorpius BioManufacturing, as a contract development and manufacturing organization (CDMO). It is focused on biologics manufacturing services. The company combines biomanufacturing expertise with advanced techniques in immunoassays and bioanalytical methods to produce cell- and gene-based therapies, as well as large molecule biologics. Its services cater to biotechnology and biopharmaceutical industries, supporting the production of cell- and gene-based therapies and large molecule biologics. Scorpius offers services, including drug substance manufacturing, release testing, and process development, supporting clients from early preclinical stages to commercial launch and addressing the growing demands in biopharmaceutical manufacturing. It operates through a storage and testing facility in San Antonio, Texas, which features modular cleanroom space and single-use bioreactors. Scorpius is headquartered in Morrisville, North Carolina, the US.
Scorpius Holdings Inc Key Recent Developments
May 05,2025: Scorpius Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
Apr 30,2025: Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
Nov 14,2024: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
Oct 31,2024: Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected To Save Over $2 Million Annually
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
50 Pages
- Section 1 - About the Company
- Scorpius Holdings Inc - Key Facts
- Scorpius Holdings Inc - Key Employees
- Scorpius Holdings Inc - Key Employee Biographies
- Scorpius Holdings Inc - Major Products and Services
- Scorpius Holdings Inc - History
- Scorpius Holdings Inc - Company Statement
- Scorpius Holdings Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 - Company Analysis
- Company Overview
- Scorpius Holdings Inc - Business Description
- Scorpius Holdings Inc - Corporate Strategy
- Scorpius Holdings Inc - SWOT Analysis
- SWOT Analysis - Overview
- Scorpius Holdings Inc - Strengths
- Scorpius Holdings Inc - Weaknesses
- Scorpius Holdings Inc - Opportunities
- Scorpius Holdings Inc - Threats
- Scorpius Holdings Inc - Key Competitors
- Section 3 - Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 - Company's Lifesciences Financial Deals and Alliances
- Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Scorpius Holdings Inc, Recent Deals Summary
- Section 5 - Company's Recent Developments
- May 05, 2025: Scorpius Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
- Apr 30, 2025: Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
- Nov 14, 2024: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
- Oct 31, 2024: Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected To Save Over $2 Million Annually
- Sep 30, 2024: Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
- Sep 09, 2024: Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
- Aug 26, 2024: Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, And Path Toward Positive Cash Flow
- Aug 20, 2024: Scorpius Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
- Aug 06, 2024: Scorpius Holdings Weighted-average Pipeline Surpasses $100 Million In Business Develop Opportunities Across Both Manufacturing Client And Government Sectors
- Jul 24, 2024: Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter
- Section 6 - Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Scorpius Holdings Inc, Key Facts
- Scorpius Holdings Inc, Key Employees
- Scorpius Holdings Inc, Key Employee Biographies
- Scorpius Holdings Inc, Major Products and Services
- Scorpius Holdings Inc, History
- Scorpius Holdings Inc, Subsidiaries
- Scorpius Holdings Inc, Key Competitors
- Scorpius Holdings Inc, Ratios based on current share price
- Scorpius Holdings Inc, Annual Ratios
- Scorpius Holdings Inc, Annual Ratios (Cont...1)
- Scorpius Holdings Inc, Annual Ratios (Cont...2)
- Scorpius Holdings Inc, Interim Ratios
- Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Scorpius Holdings Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Scorpius Holdings Inc, Performance Chart (2020 - 2024)
- Scorpius Holdings Inc, Ratio Charts
- Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
